ArticleMethods in molecular biology (Clifton, N.J.)2026
Eplontersen for the Treatment of Hereditary Transthyretin Amyloidosis.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary transthyretin-mediated amyloidosis (ATTRv) is an autosomal dominant disease and the most common form of familial amyloidosis globally. ATTRv is characterized by a mutation in the transthyretin gene that leads to the development and accumulation of amyloid fibrils in organs, specifically in the nerves and heart. This leads to the development of symptoms of cardiomyopathy and polyneuropathy in patients. The current standard of treatment consists of transthyretin-targeted therapies, including the antisense oligonucleotide (ASO) inotersen, while liver transplantation is reserved for selected patients. In 2023, a new drug, Eplontersen (brand name Wainua), was approved by the FDA for the treatment of ATTRv with polyneuropathy. Eplontersen is a second-generation ASO based on the structure of Inotersen with an important conjugation that targets the drug to hepatocytes in the liver, where it binds to the 3' untranslated region(UTR) of the transthyretin mRNA. This binding leads to the destruction of the mRNA, preventing the production of transthyretin protein, and further prevents the progression of ATTRv. This article explores the structure, mechanism of action, history of development, and future directions for the drug Eplontersen.
Indexed as
Identifiers
42814301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.